Practical legal support for health tech companies moving fast and scaling smart.
We help digital health innovators establish a firm foundation of compliance, protecting their company without slowing them down. We know healthcare, technology, startups, and–most importantly– what it takes to scale successfully in one of the most regulated industries in the world.
If you're solving problems in healthcare, we're here to help.
Digital health platforms and SaaS tools
Virtual care and telehealth providers
Remote monitoring and wearable tech companies
AI-driven healthcare solutions
Care management and patient navigation platforms
Digital Therapeutics companies
Predictive analytics platforms
Food as Medicine companies
Support at every stage.
Pre-Seed & Seed
Setting the foundation right.
Entity formation and founder agreements
Terms of service, privacy policies, and customer agreements
HIPAA and state privacy laws
IP protection
Fundraising support and term sheet review
Series A & B
Prepping for scale and serious capital.
Commercial contracts and partnership agreements
FDA, reimbursement, and fraud/abuse compliance strategy
Data use agreements
Employment agreements and employee equity incentives
Series C and Beyond
Scaling, expanding, and exit-ready.
M&A, IPO, and exit strategy support
Regulatory compliance assessment
Corporate governance and board advisory
The NLG Difference:
Why Health Tech Companies Work With Us
Healthcare First
We live in the details of healthcare law so you don’t have to.
Founder Savvy
We move at your speed and understand your realities.
Built for Scale
We grow with you, from first funding through exit.
Regulatory Edge
Compliance isn’t a cost center, it's a strategic advantage.
Top questions we’re answering lately
How does the January 2026 FDA guidance affect Clinical Decision Support (CDS) software?
1
On January 6, 2026, the FDA released revised guidance to reduce regulatory guesswork for digital health developers. The new framework clarifies which software functions are excluded from medical device regulation under the 21st Century Cures Act, specifically targeting low-risk general wellness products. Developers must now distinguish between "medical-grade" claims and general wellness to determine if their product requires formal FDA approval.
Have the federal telehealth waivers for remote prescribing been extended through 2026?
2
Yes, a fourth temporary extension currently allows DEA-registered practitioners to prescribe Schedule II-V controlled substances via telehealth without a prior in-person evaluation through December 31, 2026. This extension is intended to prevent care disruptions while permanent remote prescribing rules are finalized by federal agencies.
What are the new 2026 requirements for AI transparency in healthcare?
3
As of January 2026, several states (including Texas under HB 149) require healthcare providers to provide written disclosure to patients when AI systems are used in their treatment. Additionally, 2026 compliance audits are increasingly focusing on "Shadow AI"—the unauthorized use of AI tools by employees—which poses significant governance and data privacy risks to health organizations.
Ready to scale smarter?
Let's build a legal foundation that scales with your ambition.